Drugs cost too much. There is a better way to fund medical innovation

Drugs Medicine 2018 United Nations

UNICEF/Olivier Asselin In Côte d’Ivoire, a counsellor from UNICEF partner NGO Femme Active, instructs an adolescent boy, diagnosed with HIV in 2012, on how to take his antiretroviral (ARV) medication correctly.

This article is brought to you based on the strategic cooperation of The European Sting with the World Economic Forum.

Author: Rufus Pollock, Lead, iMed Project, and Founder and President of Open Knowledge

Drugs are expensive. Very expensive, and becoming ever more so, it seems. Prices for new medicines have been steadily rising for the past few decades. It costs a great deal to bring new drugs to market, the explanation goes, and without high prices, the pipeline of new medicines will run dry.

This argument is unsustainable, especially when even the world’s most developed economies and healthcare systems are struggling to afford vital medicines. To keep paying more for drugs simply cannot be the answer. Bad health affects everyone. We should be urgently seeking new mechanisms of funding medical innovation that do not compromise on access.

There is a strong moral and social obligation for exploring alternatives. Millions of people globally do not have access to the medicines they need to survive. In the US, millions of adults skip prescribed medications due to the high cost. The same is true in Canada, where the public healthcare system does not usually extend to cover prescription medicines, and in Europe, especially in poorer members of the EU.

The situation is worse in less developed countries. Many pay out of pocket for drugs, and the hefty price tags can run many times the annual average income. Two widely used drugs for treating hepatitis C cost the equivalent of one or more years’ average earnings in 12 out of 30 countries, revealed a recent study by the World Health Organization. Millions are dying because they cannot afford the medicine they need to stay alive.

When some members of society lack medicine, there are consequences beyond the individual directly affected. The increased morbidity caused by a lack of access to medication places an extraordinary strain on healthcare systems, exacerbating the drain on their resources from ever more expensive drugs. In addition, unhealthy populations are far less economically productive than healthy ones. Beyond social justice, there are clear economic reasons to find new models of funding medical innovation that do not restrict access to medicine.

The current state of affairs is making the world a more dangerous place. Healthcare systems that are strained by increased morbidity, and by a critical lack of money and medicine, are less likely to be able to contain outbreaks when they occur. Poor global health increases global instability. Failing to ensure everyone has access to necessary medication can have profound knock-on consequences and worsen existing crises.

Moreover, the high sale price of drugs skews incentives for innovation towards wealthy consumers. This means that vital medicines for certain ailments are not accessible when needed on a global scale. For instance, the Ebola virus had been known about for decades before the recent outbreak, and yet virtually no treatments were available. The whole world is unprepared and at risk.

The explanation that pharmaceutical companies offer for high drug prices is compelling. It costs a great deal of money to bring a drug to market, they argue. This is why so many reluctantly accept the current state of affairs, in which innovation justifies restricted access. Though it is true that drugs do cost a lot to bring to market, there is a remarkable lack of consensus on exactly how much.

This is compounded by a systemic lack of transparency. It is often not known how much is spent on what, and how reliant private-sector developments are on publicly funded research. Often, medicines that are developed with significant help from public funds do not reflect that support in prices, and there is no guarantee under the monopoly rights patent system that they should.

Moreover, a great deal of money that could be earmarked for research is spent on marketing instead. Indeed, in some large drug companies, expenditure on marketing outweighs that on research.

This model is unsustainable. So long as we continue to reward innovation through a single channel – buying the drug – access to new medicines will be limited. Ultimately, the problem is about how we pay for medicine. Today, we only pay by purchasing the end product. This means that the costs of manufacture (which is cheap) and innovation (which is expensive) are rolled into one. This puts access and innovation in conflict.

If we were to change how we fund medicines, there could be no conflict. Incentives for innovation and access to affordable drugs could co-exist. We can fund research and production separately. There is no excuse for not exploring the wide systemic changes needed to make that happen.

Today’s model is unsustainable, unhealthy and utterly unnecessary. We can have new medicines and wide access to them. We should be working towards this as a matter of urgency.

And we have ideas. For example, at the iMed Project we’ve been developing innovative two-part payment models for funding medicines that would maintain incentives for innovators while making treatment at cost of manufacture.”

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

How Japan became the world leader in floating solar power

World Health Organisation and young doctors: is there any place for improvement?

Bankers don’t go to jail because they are more equal than us all

Botswana has decriminalized gay sex. But, it’s still illegal in 70 countries

From cheeseburgers to coral reefs, the science of decision-making can change the world

Portugal’s pension system needs to prepare for rapid population ageing

Parliament adopts new rules for short-stay visas

The story of 2018, in 10 charts

EU, Brazil to hold high level Summit in Brasilia

Deutsche Bank chased away from US, threatened with more fines

Britain heading to national schism on exit from EU

EU gas market: new rules agreed will also cover gas pipelines entering the EU

Portugal: €4.66 million in aid for 1,460 dismissed workers and jobless young

Central Asia: the European Union matches political commitment with further concrete support

Is China about to launch its own cryptocurrency?

Nuclear weapons in Lithuania: defence against Russia or target for terrorists?

European Citizens’ Initiative: A game of much publicity and one big lie

How drones can help rural Africa take flight

A voice from Syria: the positive prospect of clinical research despite the excruciating circumstances

UN rights experts call on Philippines Government to halt ‘unacceptable attacks’ on Victoria Tauli-Corpuz

Draghi joined Macron in telling Germany how Eurozone must be reformed

How India’s globalized cities will change its future

Siege of Syria’s eastern Ghouta ‘barbaric and medieval’, says UN Commission of Inquiry

The opportunity of studying Medicine abroad

EU consumer rules: Airbnb cooperates with European Commission and EU consumer authorities improving the way it presents offers

Germany openly seeks more advantages for its banks

EU Budget 2019: no deal before the end of the conciliation period

UN Envoy ‘confident’ deal can be reached to avert further violence around key Yemeni port city

EU-Russia relations: the beginning of a warmer winter?

Erdogan’s electoral win on a ‘me or chaos’ dilemma means trouble for everybody

MEPs cap prices of calls within EU and approve emergency alert system

MEPs want robust EU cyber defence and closer ties with NATO

Climate change recognized as ‘threat multiplier’, UN Security Council debates its impact on peace

1.4 million refugees set to need urgent resettlement in 2020: UNHCR

What little Cameron got in Brussels seems enough to keep Britain in the EU

Sustainable development funding is broken. Here’s how to fix it

Take-home pay growing at lowest level since 2008, as gender-gap persists: UN labour agency

EU opens a third antitrust file against Google

UNESCO experts ready to assist reconstruction of iconic Notre Dame, following devastating blaze

UN rights experts call on Russia to release Ukrainian film-maker whose life is in ‘imminent danger’

In this Tokyo cafe, the waiters are robots operated remotely by people with disabilities

EU imposes provisional anti-dumping tariffs on Chinese solar panels

UN welcomes ‘milestone’ release of 833 Nigerian children from anti-Boko Haram force

Ethiopia is Africa’s fastest-growing economy

Mali’s ‘self-defence’ groups must face justice, after deadly intercommunal attacks

Factories are no longer the sure route to prosperity. Here’s why

UN cooperation with League of Arab States ‘pivotal’, UN chief tells Security Council

Parliament votes reform for better European Co2 market but critics want it sooner than later

Outgoing UN official praises Iraq’s ‘exemplary peaceful transfer of power’ at the top

EU to scrutinise foreign direct investment more closely

The world’s landmine stockpiles in numbers

South Sudan ‘heading towards lasting peace and stability’, UN General Assembly told

These are the United States’ most exported products

Google and Apple suddenly realise that doing business in EU is tough?

A Sting Exclusive: Young people are right about climate change; it’s time to listen

Alexis Tsipras against internal and external “enemies” in pursue of a two-phase deal now

EU Banks still get subsidies from impoverished citizens

Libya: Thousands seek shelter in health clinics from Tripoli fighting, UN warns

Disintegrating Tories will void May’s pledge for Brexit deal in seven weeks

The cost of housing is tearing our society apart

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s